Elixir Clinical Research Funding: $52M Raised, Series A1
Elixir Clinical Research is based in Shanghai, China. It has raised $52M in total funding. Latest round: Series A1.
Elixir Clinical Research funding overview
Elixir Clinical Research is based in Shanghai, China. Elixir Clinical Research has raised $52M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A1 announced in January 2024. The round record for Elixir Clinical Research runs through 2024; nothing later has been disclosed. Investors on record include LYFE Capital, Sinovation Ventures, Chow Tai Fook. 3 distinct backers are named across the disclosed rounds.
Elixir Clinical Research at a glance
Total raised
$52M
Latest round
Series A1
Latest round date
January 2024
Headquarters
Shanghai, China
Notable investors
LYFE Capital, Sinovation Ventures, Chow Tai Fook
Frequently asked about Elixir Clinical Research funding
How much has Elixir Clinical Research raised?
Elixir Clinical Research has raised $52M in total disclosed funding across the rounds on record.
Who has invested in Elixir Clinical Research?
LYFE Capital, Sinovation Ventures, Chow Tai Fook are named among the investors backing Elixir Clinical Research.
What was the latest Elixir Clinical Research funding round?
The most recent disclosed round is a Series A1, announced in January 2024.
Where is Elixir Clinical Research based?
Elixir Clinical Research is based in Shanghai, China.
When did Elixir Clinical Research last raise?
The last disclosed Elixir Clinical Research round closed in January 2024 at Series A1.
Round data for Elixir Clinical Research is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Shanghai and backer lists below.
Companies related to Elixir Clinical Research (31)
